Achieve Life Sciences, Inc. (ACHV)

Market Cap	146.02M
Revenue (ttm)	n/a
Net Income (ttm)	-46.16M
Shares Out	34.69M
EPS (ttm)	-1.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	917,757
Open	3.940
Previous Close	3.900
Day's Range	3.855 - 4.300
52-Week Range	1.840 - 5.580
Beta	1.64
Analysts	Strong Buy
Price Target	14.33 (+240.38%)
Earnings Date	May 13, 2025

About ACHV

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc., which is headquartered in Vancouver, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Richard A. Stewart
• Employees: 25
• Stock Exchange: NASDAQ
• Ticker Symbol: ACHV
• Website: https://www.achievelifesciences.com

Analyst Forecast

According to 3 analysts, the average rating for ACHV stock is "Strong Buy." The 12-month stock price forecast is $14.33, which is an increase of 240.38% from the latest price.

Price Target

$14.33

(240.38% upside)

Analyst Consensus: Strong Buy